Congenital vascular lesions, could MAPK and PI3K inhibitors pave the way to new therapies?
Animals
Humans
MAP Kinase Signaling System
/ drug effects
Mitogen-Activated Protein Kinases
/ antagonists & inhibitors
Molecular Targeted Therapy
Phosphatidylinositol 3-Kinases
/ metabolism
Protein Kinase Inhibitors
/ therapeutic use
Proto-Oncogene Proteins c-akt
/ metabolism
Sirolimus
/ therapeutic use
TOR Serine-Threonine Kinases
/ antagonists & inhibitors
Vascular Neoplasms
/ congenital
ras Proteins
/ metabolism
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
pubmed:
23
1
2021
medline:
6
8
2021
entrez:
22
1
2021
Statut:
ppublish
Résumé
Superficial vascular anomalies are a heterogeneous group of malformative and tumoral lesions, developed from various types of abnormal lymphatic and/or blood vessels. They are mostly benign but their clinical evolution can lead to dramatic cosmetic concern, functional impairment and even life-threatening conditions. Until recently, treatments relied on invasive procedures such as embotherapy/sclerotherapy and/or surgery. Recent molecular findings pave the way of new medical therapies. Two main signaling pathways PI3K-AKT-mTOR and RAS-MAPK-ERK are now identified to encounter for the causative pathogenic genetic variants of most vascular anomalies. Involved genes are also responsible for several common neoplasms for which targeted therapies are already available or under development. Repurposing treatment strategy is considered for vascular anomalies treatment with promising results. The mTOR inhibitor sirolimus is the most used targeted therapy so far but new molecules are tested currently.
Identifiants
pubmed: 33481427
doi: 10.1097/CCO.0000000000000712
pii: 00001622-202103000-00002
doi:
Substances chimiques
Protein Kinase Inhibitors
0
MTOR protein, human
EC 2.7.1.1
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
Mitogen-Activated Protein Kinases
EC 2.7.11.24
ras Proteins
EC 3.6.5.2
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
95-100Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children. Plast Reconstr Surg 1982; 69:412–420.
Wassef M, Blei F, Adams D, et al. ISSVA Board and Scientific Committee. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics 2015; 136:e203–e214.
International Society for the Study of Vascular Anomalies. Classification of vascular anomalies. 2018 (May).
Nathan N, Keppler-Noreuil KM, Biesecker LG, et al. Mosaic disorders of the PI3K/PTEN/AKT/TSC/mTORC1 signaling pathway. Dermatol Clin 2017; 35:51–60.
Lekwuttikarn R, Lim YH, Admani S, et al. Genotype-guided medical treatment of an arteriovenous malformation in a child. JAMA Dermatol 2019; 155:256–257.
Van Damme A, Seront E, Dekeuleneer V, et al. New and emerging targeted therapies for vascular malformations. Am J Clin Dermatol 2020; 21:657–668.
Ten Broek RW, Eijkelenboom A, Vleuten CJM, et al. Comprehensive molecular and clinicopathological analysis of vascular malformations: a study of 319 cases. Genes Chromosomes Cancer 2019; 58:541–550.
Amyere M, Aerts V, Brouillard P, et al. Somatic uniparental isodisomy explains multifocality of glomuvenous malformations. Am J Hum Genet 2013; 92:188–196.
Macmurdo CF, Wooderchak-Donahue W, Bayrak-Toydemir P, et al. RASA1 somatic mutation and variable expressivity in capillary malformation/arteriovenous malformation (CM/AVM) syndrome. Am J Med Genet Part A3 2016; 170:1450–1454.
Snellings DA, Gallione CJ, Clark DS, et al. Somatic mutations in vascular malformations of hereditary hemorrhagic telangiectasia result in bi-allelic loss of ENG or ACVRL1. Am J Hum Genet 2019; 105:894–906.
Ola R, Dubrac A, Han J, et al. PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia. Nat Commun 2016; 7:13650.
Shirley MD, Tang H, Gallione CJ, et al. Sturge-weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med 2013; 368:1971–1979.
Couto JA, Ayturk UM, Konczyk DJ, et al. A somatic GNA11 mutation is associated with extremity capillary malformation and overgrowth. Angiogenesis 2017; 20:303–306.
Li D, March ME, Gutierrez-Uzquiza A, et al. ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. Nat Med 2019; 25:1116–1122.
Li D, Wenger TL, Seiler C, et al. Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly. Hum Mol Genet 2018; 27:3233–3245.
Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57:1018–1024.
Maruani A, Boccara O, Bessis D, et al. Groupe de Recherche de la Societé Française de Dermatologie Pédiatrique. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design. Trials [Internet] 2018; 19:340.
Adams DM, Trenor CC, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics 2016; 137:e20153257.
Rössler J, Geiger J, Földi E, et al. Sirolimus is highly effective for lymph leakage in microcystic lymphatic malformations with skin involvement. Int J Dermatol 2017; 56:e72–e75.
Hammer J, Seront E, Duez S, et al. Sirolimus is efficacious in treatment for extensive and/or complex slow-flow vascular malformations: a monocentric prospective phase II study. Orphanet J Rare Dis 2018; 13:191.
Salloum R, Fox CE, Alvarez-Allende CR, et al. Response of blue rubber bleb nevus syndrome to sirolimus treatment. Pediatr Blood Cancer 2016; 63:1911–1914.
Parker VER, Keppler-Noreuil KM, Faivre L, et al. Safety and efficacy of low-dose sirolimus in the PIK3CA-related overgrowth spectrum. Genet Med 2019; 21:1189–1198.
Meurisse V, Denamur S, Herbreteau D, et al. Efficacy of sirolimus combined with scle- rotherapy for giant cervical lymphatic macrocystic malformations: two newborn cases. Eur J Dermatol 2019; 29:88–90.
Dodds M, Tollefson M, Castelo-Soccio L, et al. Treatment of superficial vascular anomalies with topical sirolimus: a multicenter case series. Pediatr Dermatol 2020; 37:272–277.
Badia P, Ricci K, Gurria JP, et al. Topical sirolimus for the treatment of cutaneous manifestations of vascular anomalies: a case series. Pediatr Blood Cancer 2020; 67:e28088.
Leducq S, Caille A, Barbarot S, et al. Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial. Trials 2019; 20:739.
Boccara O, Puzenat E, Proust S, et al. The effects of sirolimus on Kasabach-Merritt phenomenon coagulopathy. Br J Dermatol 2018; 178:e114–e116.
Boccara O, Hadj-Rabia S, Bourrat E, et al. Rapamycin-associated lymphoedema in an infant with Kasabach-Merritt phenomenon. Br J Dermatol 2016; 174:933–934.
Gabeff R, Boccara O, Soupre V, et al. Efficacy and tolerance of sirolimus (rapamycin) for extracranial arteriovenous malformations in children and adults. Acta Derm Venereol 2019; 99:1105–1109.
Venot Q, Blanc T, Rabia SH, et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature [Internet] 2018; 558:540–546.
Limaye N, Wouters V, Uebelhoer M, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 2009; 41:118–124.
Li X, Cai Y, Goines J, et al. Ponatinib combined with rapamycin causes regression of murine venous malformation. Arterioscler Thromb Vasc Biol 2019; 39:496–512.
Biesecker LG, Edwards M, O’Donnell S, et al. Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092). Mol Case Stud [Internet] 2020; 6:a004549.